- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Chorioretinitis
Chorioretinitis is a particularly dangerous eye disease because it targets the choroid and retina, which can result in loss of vision if not properly treated. Diagnostics and therapeutics development for chorioretinitis are within the scope of services we provide at Protheragen. With our preclinical research and development capabilities, we customize and apply extensive procedural strategies designed around every single one of our client's needs.
Chorioretinitis belongs to the group of posterior uveitis and it includes inflammatory changes of the choroid and retina. It falls under the general classification of uveitis which includes inflammatory disease of the uveal tract and adjacent tissues which may include the retina, retinal blood vessels, vitreous body, optic disc, and sclera. The choroid, as it is noted, is the vascular bed of the eye which supplies blood to the outer part of the retina. In this condition, the choroid is especially important. Inflammation of these layers can cause serious and blinding complications.
Fig.1 Mean VQF-25 results in birdshot chorioretinitis. (Kaisari E., et al., 2025)Imaging Diagnostics
Optical coherence tomography (OCT) is a non-invasive imaging technique used to acquire high-resolution cross-sectional images of the retina and choroid. It is particularly effective in identifying subretinal fluid, choroidal thickening, and retinal detachment due to chorioretinitis. Fluorescein angiography (FA) is another diagnostic test that helps in the visual depiction of the retinal and choroidal vasculature, as it depicts areas of leakage, ischemia, and neovascularization which is useful in the management of the condition.
Laboratory Diagnostics
PCR is very useful when dealing with ocular fluids as it can pinpoint specific pathogens. An example would be PCR identifying Toxocara DNA in patients that have bilateral granulomatous chorioretinitis. Diagnostic procedures like QFT-Plus or Quantiferon-TB Gold are also helpful serological tests when it comes to determining chorioretinitis associated with tuberculosis. Furthermore, the presence of certain antibodies and antigens in the cases's blood can aid in the diagnosis of autoimmunity or infection causing the disorder.
| Therapeutics | Target | Description | Stage |
| Ganciclovir | Cytomegalovirus (CMV) | An antiviral agent used to treat CMV retinitis. It inhibits viral DNA synthesis and is effective in both intravenous and intravitreal forms. | Approved |
| Valganciclovir | CMV | An oral prodrug of ganciclovir, used for systemic therapeutic of CMV retinitis. It provides a convenient once-daily dosing option. | Approved |
| Foscarnet | CMV | An antiviral that inhibits viral DNA polymerase. It is used in cases of ganciclovir-resistant CMV infections. | Approved |
| Prednisolone | Inflammatory response | A corticosteroid used to suppress inflammation in non-infectious chorioretinitis. It can be administered systemically or locally. | Approved |
| Mycophenolate Mofetil | Immune response | An immunosuppressive agent used in steroid-resistant cases or to minimize steroid-related complications. | Approved |
| Methotrexate | Immune response | An immunosuppressive agent used to manage severe inflammatory cases of chorioretinitis. | Approved |
| Adalimumab | TNF-alpha | A biologic agent used as an immunomodulator in cases where first-line therapeutics fail. | Approved |
| Infliximab | TNF-alpha | Another biologic agent targeting TNF-alpha, used in refractory cases of non-infectious chorioretinitis. | Approved |
| Bevacizumab | VEGF | An anti-VEGF agent used to treat complications such as choroidal neovascularization. | Approved |
| Ranibizumab | VEGF | Another anti-VEGF agent used for similar complications as bevacizumab. | Approved |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
The development of effective diagnostics and therapeutics for chorioretinitis requires a multidisciplinary approach, combining expertise in molecular biology, immunology, and pharmacology. As a professional research service provider, Protheragen has the ability to provide one-stop chorioretinitis diagnostics and therapy development services.
Protheragen's preclinical research services are designed to provide a solid foundation for the successful transition of chorioretinitis therapeutics from the laboratory to the clinic. We offer a range of services, including in vitro and in vivo studies to assess the efficacy and safety of therapeutic candidates. If you are interested in our services, please feel free to contact us.
Reference
Copyright © Protheragen. All rights reserved.